PBYI

6.9702.11%
BM

Brian M. Stuglik

Independent Director

Mr. Brian M. Stuglik, B.Pharm, RPh, had been the Chief Executive Officer of Verastem, Inc. since July 29, 2019 until August 1, 2023. Mr. Stuglik serves as an Independent Director of Puma Biotechnology, Inc. since July 5, 2020. Mr. Stuglik served as Chief Marketing Officer at Lilly Oncology from 2009 to December 2015. Mr. Stuglik has experience in pharmaceutical and oncology commercialization in both the U.S. and international markets. Mr. Stuglik has provided commercial and strategic consultancy services to a variety of life science companies as the founder of Proventus Health Solutions, LLC in January 2016. Prior to Proventus, he served for over 30 years at Eli Lilly and Company, as Global Vice President of Oncology Global Marketing and advancing Lilly Oncology from a single brand and approved product to a portfolio of over 6 marketed or late-stage compounds across more than 10 cancer types. While at Lilly, Mr. Stuglik lead the efforts to acquire Imclone Systems and later led the integration and transition team for Lilly. Mr. Stuglik is an accomplished executive with significant oncology commercialization expertise. He has commercializing important novel oncology drugs together with his extensive external network of clinical thought leaders and deep industry connections. He has successfully launched several multi-billion dollar brands over his career, including Gemzar(R), Alimta(R) and Erbitux(R). He has been a Director at Verastem, Inc. since September 2017. He holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research and the International Association for the Study of Lung Cancer. Mr. Brian Stuglik has been a Director of Oncopeptides AB (publ) since May 17, 2018. Mr. Stuglik received B.S. in Pharmacy from Purdue University.

Positions